The IPML is responsible for study medical/safety aspects and risk-benefit assessments supported by Pharmacovigilance and Clinical Science; Is accountable for the timely delivery of milestones, mitigates roadblocks and is empowered to take decisions to effectively execute on the clinical strategy; Supports the preclinical evaluation and validation of new oncology assets in line with the overarching RED ONC strategy focusing on value, differentiation, and unmet medical need (e.g., through interacting with BD&L, LEAPS, Collaboration to Cure Hubs, CoLab incubator); In alignment with the overall ECDO and RED-ONC strategy, identifies new opportunities for collaboration and manages excellent relationships with new and existing partners, both within as well as outside of Bayer, to drive clinical excellence; Can lead and drive ECDO-initiated (cross-)functional strategic initiatives in support of the overall ECDO, RED-ONC, Oncology and/or Bayer strategy; can act as a representative of ECDO in other cross-functional activities and workstreams where required. As such, the IPML takes accountability for the respective team outcomes and promotes a creative and innovation-friendly collaboration between clinicians and scientists; Takes accountability for the respective team outcomes and promotes a creative and innovation-friendly collaboration between clinicians and scientists; Takes ownership for the entire ECDO team, fosters a culture of ownership in support of the strategy and in line with Bayer's values; empowers others and drives peer accountability across portfolio deliverables and beyond; Evolves ECDO's unique value contribution and thereby drives the development of a productive and fulfilled workforce by embracing a culture of creativity and innovation, while ensuring that capabilities are available and actively evolving accountability across portfolio deliverables and beyond.